Geert Maertens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11898541/publications.pdf

Version: 2024-02-01

361045 525886 5,624 31 20 27 citations h-index g-index papers 31 31 31 4150 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology, 2005, 42, 962-973.	3.6	1,303
2	Long-Term Outcome of Hepatitis C Infection after Liver Transplantation. New England Journal of Medicine, 1996, 334, 815-821.	13.9	969
3	A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology, 1994, 19, 1321-1324.	3.6	962
4	Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nature Medicine, 2000, 6, 578-582.	15.2	697
5	Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology, 1995, 108, 1088-1096.	0.6	296
6	Genotypic analysis of hepatitis C virus in American patients. Hepatology, 1994, 20, 1405-1411.	3.6	195
7	Hepatitis C virus genotyping by means of 5′-UR/core line probe assays and molecular analysis of untypeable samples. Virus Research, 1995, 38, 137-157.	1.1	149
8	A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology, 2003, 38, 1289-1296.	3.6	119
9	Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. Journal of Translational Medicine, 2016, 14, 95.	1.8	117
10	Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa. Journal of Medical Virology, 1998 , 55 , $92-97$.	2.5	112
11	Hepatitis C virus in a hemodialysis unit: Molecular evidence for nosocomial transmission. Kidney International, 1996, 49, 889-895.	2.6	97
12	<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Molecular Cancer Therapeutics, 2016, 15, 1397-1404.	1.9	78
13	A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine, 2004, 22, 3080-3086.	1.7	74
14	Inhibition of Hepatitis C Virus-Like Particle Binding to Target Cells by Antiviral Antibodies in Acute and Chronic Hepatitis C. Journal of Virology, 2004, 78, 9030-9040.	1.5	70
15	Analysis of hepatitis C virus genotypes by a line probe assay and correlation with antibody profiles. Journal of Hepatology, 1994, 21, 122-129.	1.8	61
16	High-level transient expression of influenza virus proteins from a series of SV40 late and early replacement vectors. Gene, 1988, 66, 163-181.	1.0	51
17	<i>BRAF</i> mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget, 2015, 6, 26886-26894.	0.8	45
18	HCV genotypes in patients with liver disease of different stages and severity. Journal of Hepatology, 1997, 26, 1173-1178.	1.8	43

#	Article	IF	CITATIONS
19	Clearance of Genotype 1b Hepatitis C Virus in Chimpanzees in the Presence of Vaccine-Induced E1-Neutralizing Antibodies. Journal of Infectious Diseases, 2011, 204, 837-844.	1.9	41
20	Rapid detection of hepatitis C virus RNA by direct capture from blood. Journal of Medical Virology, 1994, 42, 22-28.	2.5	23
21	ANTIBODIES TO HEPATITIS C VIRUS ENVELOPE PROTEINS CORRELATE WITH HEPATITIS C VIRAEMIA AFTER LIVER TRANSPLANTATION. Transplantation, 1999, 67, 78-84.	0.5	19
22	Recombinant secreted haemagglutinin protects mice against a lethal challenge of influenza virus. Vaccine, 1993, 11, 1185-1187.	1.7	17
23	Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers. , 2000, 60, 126-132.		17
24	Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma. Melanoma Research, 2016, 26, 157-163.	0.6	16
25	Hepatitis C virus antibody detection by a line ImmunoAssay and (near) full length genomic RNA detection by a new RNA-capture polymerase chain reaction. Journal of Medical Virology, 1992, 38, 298-304.	2.5	12
26	Postâ€transplant recurrent hepatitis C: immunohistochemical detection of hepatitis C virus core antigen and possible pathogenic implications. Liver International, 2008, 28, 807-813.	1.9	12
27	Serological and molecular analysis of hepatitis C virus envelope regions 1 and 2 during acute and chronic infections in chimpanzees., 1997, 52, 441-450.		11
28	Detection of neutralizing antibodies to hepatitis C virus using a biliary cell infection model. Journal of General Virology, 2002, 83, 1673-1678.	1.3	10
29	Characterization and Clinical Utility of BRAFV600 Mutation Detection Using Cell-Free DNA in Patients with Advanced Melanoma. Cancers, 2021, 13, 3591.	1.7	4
30	HCV Genotyping by the Line Probe Assay INNO-LiPA HCV II. , 1999, 19, 183-198.		3
31	Low Prevalence of Anti-E1 Antibodies Reactive to Recombinant Type 1b E1 Envelope Protein in Type 2, 3, and 4 HCV Sera, but High Prevalence in Subtypes 1a and 1b., 1994,, 314-316.		1